Sign in
Taking peoplePhase 3

Tests AZD0120 cell therapy after standard treatment in adults with newly diagnosed multiple myeloma

Tests AZD0120 cell therapy in adults with newly diagnosed multiple myeloma.

Key facts

Who runs it
AstraZeneca
Where
Seoul, South KoreaSee the siteAlso in 14 other countries, 109 sites
Trial code
Registry title
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Status
Recruiting
Phase
Phase 3
People taking part
750 people, planned
Started
26 Jun 2026
Expected to end
12 May 2034
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • AZD0120
  • Daratumumab
  • Dexamethasone
  • Isatuximab
  • Lenalidomide
  • Bortezomib
  • Cyclophosphamide
  • Fludarabine
Record updated
14 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed multiple myeloma who cannot have an autologous stem cell transplant as first treatment.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Newly diagnosed multiple myeloma with measurable disease (blood or urine M-protein, or free light chains), ECOG performance status 0 to 2, and not able to have an autologous stem cell transplant (ASCT).
Earlier treatment
This is initial treatment. The person must be a candidate for at least one of the regimens IsaVRd or DRd.
Biomarker or test result
Measurable disease: serum M-protein ≥1.0 g/dL, or urine M-protein ≥ 200 mg/24 h, or serum immunoglobulin FLC ≥ 10 mg/dL (100 mg/L) with an abnormal kappa lambda FLC ratio.

Main reasons for not taking part

  • Cancer involvement of the brain or its linings (CNS or meningeal) now or in the past
  • Primary amyloidosis, active plasma cell leukemia, Waldenström macroglobulinemia or POEMS syndrome
  • Known HIV, chronic or active hepatitis B, or active hepatitis C
  • Another blood cancer in the past, or another cancer not disease-free for at least 2 years
  • Clinically significant heart disease, or COPD with FEV1 < 50% of predicted normal

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Participants must be 18 years or older, at the time of signing the ICF
  • Participant must have documented diagnosis of MM according to the IMWG diagnostic criteria
  • Participant must have one or more of the following measurable disease criteria: (a) Serum M-protein level ≥1.0 g/dL, (b) Urine M-protein level ≥ 200 mg/24 h, (c)Serum immunoglobulin FLC ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda FLC ratio
  • Participant must be deemed ineligible for ASCT while also having adequate organ function for CAR-T cell treatment
  • Participant is a candidate to receive at least one of the regimens (IsaVRd or DRd) as determined by the Investigator
  • ECOG performance status Grade of 0 to 2
  • Participant must have adequate organ and bone marrow function

Who cannot take part

  • Participant has active or prior CNS or meningeal involvement of MM
  • Participant has a history of a prior non-haematologic malignancy unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years
  • Participant has primary amyloidosis, active plasma cell leukemia (≥5% circulating plasma cells), Waldenström macroglobulinemia, or POEMS syndrome
  • Participant has significant neurological or psychiatric condition posing risk or impairing evaluation
  • Participant has any other significant medical condition that increases unacceptable risk, interferes with therapy delivery, or confounds evaluation
  • Participant has a history of haematologic malignancies, other than MM, regardless of remission status
  • Participant is positive for any of the following:; HIV: Known to be seropositive for HIV (including any history of HIV); Chronic or active hepatitis B; Active hepatitis C: Hepatitis C infection; Additional local requirements for the testing for infectious diseases and exclusions of applicable participants should be followed per local regulations
  • Participant has clinically significant cardiovascular disease
  • Participant has COPD with an FEV1 < 50% of predicted normal
  • Additional exclusion for participants who are planned to receive IsaVRd as induction: Participant has peripheral neuropathy Grade 4, Grade 3, Grade 2, or Grade 1 with pain

Where in South Korea

Also in 14 other countries, 109 sites

  • SeoulHospital not named in the registryNot yet recruiting

About the trial

What the trial wants to find out

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.

The 2 groups in the trial

  • Arm A: Investigational ArmTreatment being tested

    Arm A is the sequence of induction with IsaVRd or DRd, apheresis, optional bridging therapy, lymphodepletion (cyclophosphamide and fludarabine), and AZD0120.

    Treatment: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, Bortezomib, Cyclophosphamide, and Fludarabine

  • Arm B: Control ArmExisting treatment, for comparison

    Arm B is the standard therapy induction with IsaVRd or DRd, followed by continuous IsaRd or DRd until disease progression or intolerable toxicity.

    Treatment: Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, and Bortezomib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)
Plain-language title
Tests AZD0120 cell therapy after standard treatment in adults with newly diagnosed multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 August 2026